Evidence map›Paper›PMID 41736019›Full record

ArticleCell communication and signaling : CCS2026

Correction: Harnessing nanomedicine to target NFκB signalling in cancer: at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation.

Bandari BharathwajChetty, Babu Santha Aswani, Shweta S Shinde, Mohammed S Alqahtani, Mohamed Abbas, Gautam Sethi, Zhaowu Ma, Ajaikumar B Kunnumakkara

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Bandari BharathwajChettyDepartment of Biosciences and Bioengineering, Cancer Biology Laboratory, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, India.ORCID http://orcid.org/0000-0002-4147-3993
Babu Santha AswaniDepartment of Biosciences and Bioengineering, Cancer Biology Laboratory, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, India.ORCID http://orcid.org/0009-0003-2763-5671
Shweta S ShindeDepartment of Biosciences and Bioengineering, Cancer Biology Laboratory, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, India.
Mohammed S AlqahtaniRadiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha, 61421, Saudi Arabia.
Mohamed AbbasElectrical Engineering Department, College of Engineering, King Khalid University, Abha, 61421, Saudi Arabia.
Gautam SethiDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117600, Singapore.ORCID http://orcid.org/0000-0002-8677-8475
Zhaowu MaSchool of Basic Medicine, Health Science Center, Yangtze University, Jingzhou , 434023, China. mazw@yangtzeu.edu.cn.
Ajaikumar B KunnumakkaraDepartment of Biosciences and Bioengineering, Cancer Biology Laboratory, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, India. kunnumakkara@iitg.ac.in.ORCID http://orcid.org/0000-0001-9121-6816

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41736019
PMCPMC12934033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.